AB Science SA (Euronext - FR0010557264 - AB) today announced that the Chinese Patent Office has issued a patent relating to methods of treating severe acute respiratory syndrome coronavirus 2 ...

AB SCIENCE WILL HOST A LIVE WEBCAST ON MONDAY DECEMBER 16, 2024 FROM 5.30PM TO 6.30PM CET Paris, 11 December, 2024, 6pm CET AB Science SA (Euronext – FR0010557264 – AB) will host a live webcast on ...

AB Science SA (Euronext - FR0010557264 - AB) today announced that it has filed an application for conditional Marketing Authorization to the European Medicines Agency (EMA) for Alsitek (masitinib) in ...

The average one-year price target for AB Science (ENXTPA:AB) has been revised to €4.31 / share. This is an increase of 22.25% from the prior estimate of €3.53 dated September 27, 2025. The price ...

FOLLOWING RELEASE OF FYE2025 RESULTS AND SECURING OF CLINICAL TRIAL INSURANCE POLICY, MAXIM GROUP REITERATES ITS BUY RECOMMENDATION ON AB SCIENCE'S STOCK WITH A TARGET PRICE OF EUR 4.0 PER SHARE Paris ...

PRESS RELEASE AB SCIENCE ANNOUNCES THE SUCCESSFUL COMPLETION OF A EUR 2.3 MILLION PRIVATE PLACEMENT Paris, July 1st, 2026, 8am AB Science S.A. (the "Company" or "AB Science", Euronext - FR0010557264 ...

FOLLOWING RELEASE OF FYE2025 RESULTS AND SECURING OF CLINICAL TRIAL INSURANCE POLICY, MAXIM GROUP REITERATES ITS BUY RECOMMENDATION ON AB SCIENCE'S STOCK WITH A TARGET PRICE OF EUR 4.0 PER SHARE AB ...

AB Science SA (Euronext - FR0010557264 - AB) today announces that Health Canada has issued a Notice of Non-Compliance-Withdrawal (NON/w) regarding its New Drug Submission (NDS) for masitinib in the ...

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Skuldtech, a genomic and pharmacogenomic company specialized in developing diagnostic tests, and AB Science (NYSE Euronext – FR0010557264 – AB), ...